Research concludes professional disease education leads to greater treatment adoptions.
Through its Veeva Pulse Field Trends Report, Veeva Systems has announced the findings of field medical's impact on clinical practice. According to the report’s analysis, disease state education by medical science liaisons (MSLs) with key opinion leaders (KOLs) before launch leads to 1.5 times greater treatment adoption.
Reportedly, scientific engagement with KOLs provides an enduring impact on new treatment adoption. Despite this discovery, 70% only engage with one company's field medical team, leaving a need for better field planning and connected insights across organizations.
"The right data is foundational to our engagement strategy. We can quickly identify who the relevant KOLs are and organize those KOLs based on when and where they are sharing scientific information and what scientific information they are sharing," said Christine Castro, director of medical affairs excellence, Lundbeck, in a company press release. "As we prepared for the launch of new treatments, this data-driven approach helped us build the right relationships and focus our resources where they will have the greatest scientific impact."
Reference: Veeva Pulse Uncovers Field Medical Engagement Drives 1.5x Increase in Treatment Adoption. PR Newswire. July 26, 2023. Accessed July 28, 2023. https://www.prnewswire.com/news-releases/veeva-pulse-uncovers-field-medical-engagement-drives-1-5x-increase-in-treatment-adoption-301885869.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.